Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377812 | 1.00 | HTT (0.35) | HTTKMT2APLAUDYRK1A | |
| SCHEMBL21591696 | 0.86 | HTT (0.32) | HTTKMT2A | |
| SCHEMBL21591595 | 0.86 | DYRK1A (0.32) | HTTKMT2ADYRK1A | |
| SCHEMBL21591588 | 0.83 | PLAU (0.31) | HTTKMT2APLAUDYRK1A | |
| SCHEMBL21591653 | 0.81 | ALDH1A1 (0.32) | — | |
| SCHEMBL856508 | 0.78 | KMT2A (0.37) | HTTKMT2APLAUDYRK1A | |
| SCHEMBL31430877 | 0.78 | KMT2A (0.37) | HTTKMT2APLAUDYRK1A | |
| SCHEMBL29159933 | 0.78 | PLAU (0.43) | HTTKMT2APLAUDYRK1A | |
| SCHEMBL24567435 | 0.77 | KMT2A (0.54) | HTTKMT2APLAUDYRK1A | |
| SCHEMBL2112705 | 0.77 | S1PR1 (0.39) | HTTKMT2APLAUDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-3983416-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-12344621-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-12227521-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| WO-2024153947-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-07-25 | — | — | WO | disclosed |
| US-20240043439-A1 | COMPOUNDS AS C5AR INHIBITORS | KIRA PHARMACEUTICALS (SUZHOU) LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-09-29 | — | — | US | disclosed |
| US-20140011827-A1 | PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011827-A1 | PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2014-01-09 | — | — | US | disclosed |
| WO-2012129013-A1 | PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-09-27 | — | — | WO | disclosed |
| EP-0643716-B1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMA (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5763611-A | TREATING OSTEOPOROSIS, RHEUMATOID ARTHRITIS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-09 | — | — | US | disclosed |
| US-5753634-A | TREATING OR PREVENTING ARTHRITIS AND OSTEOPOROSIS | THE PROCTER & GAMBLE COMPANY (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0643716-A1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | THE PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0642520-A1 | THIO-SUBSTITUTED CYCLIC PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993024497-A1 | THIO-SUBSTITUTED CYCLIC PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024499-A1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | HTT 3040/4885KMT2A 4547/4885PLAU 2323/4885 |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, CALCA | HTT 2676/4885KMT2A 4367/4885PLAU 2535/4885 |
| US-20240043439-A1 | COMPOUNDS AS C5AR INHIBITORS | C5AR1, C5AR2, C3AR1 | HTT 4089/4885KMT2A 4744/4885PLAU 231/4885 |
| US-12227521-B2 | CGRP antagonist compounds | CALCRL, CALCR, OPRL1 | HTT 3040/4885KMT2A 4547/4885PLAU 2323/4885 |
| US-12344621-B2 | CGRP antagonist compounds | CALCRL, CALCR, CALCA | HTT 2704/4885KMT2A 4392/4885PLAU 2502/4885 |
| US-20140011827-A1 | PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | HTT 1088/4885KMT2A 2673/4885PLAU 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.